Cantor Fitzgerald reiterates Overweight on Capricor stock ahead of FDA decision

Cantor Fitzgerald reiterates Overweight on Capricor stock ahead of FDA decision

Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.